<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Hold Off on Approving Anal Cancer Drug, Advisors Tell FDA

minute read.

Written by MedPage Today on June 24, 2021

FDA advisors told the agency to wait on more data before approving an investigational immunotherapy for squamous carcinoma of the anal canal (SCAC), largely due to questions over the drug's activity.

Topics: Press Coverage

Comments